Company Overview
electroCore, Inc., a bioelectronic technology medicine and general wellness company, provides non-invasive vagus nerve stimulation (nVNS) technology platform in the United States, the United Kingdom, and internationally. The company develops gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga 350, a personal use consumer electronics general wellness product and Truvaga Plus, an app-enabled general wellness product. It also offers non-invasive bioelectronic therapies for the treatment of chronic pain and wellness conditions. In addition, the company offers TAC-STIM for human performance and gammaCore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
Why Investors Should Care
Revenue has grown at a 58.3% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $32.03M (+27.2% YoY); net profit $-13.97M.
- Trailing 12 Months Year-on-year growth — revenue +28.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 58.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 58.32% |
| 1 Year: | 28.00% |
Stock Price Performance
| 1 Year: | +76.65% |
| 6 Months: | +36.75% |
| 3 Months: | -5.81% |
| 1 Month: | +12.24% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)50.78 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 58.3% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ECOR electroCore, Inc. PHARMA | 9.08 | -5.50 | $81.86M | 0.00% | - | - | 58.32% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 117.00K | 177.00K | 283.00K | 234.00K | 81.19K | 393.23K | 150.97K | 368.00K | 409.60K | 622.74K | 682.99K | 733.77K | 752.96K | 1.08M | 1.20M | 1.27M | 1.49M | 1.90M | 2.16M | 1.98M | 2.78M | 3.55M | 4.51M | 5.44M | 6.14M | 6.55M | 6.72M | 7.38M | 8.69M | 9.58M | 9.45M |
| Gross Profit | - | 137.81K | 154.92K | - | 32.24K | 152.74K | 53.91K | - | 251.81K | 368.30K | 329.05K | 435.66K | 479.97K | 733.34K | 840.00K | 895.00K | 1.13M | 1.54M | 1.80M | 1.72M | 2.32M | 2.97M | 3.85M | 4.55M | 5.30M | 5.49M | 5.71M | 6.44M | 7.47M | 8.36M | 8.18M |
| Operating Income | -4.74M | -7.43M | -5.99M | -7.49M | -9.10M | -16.22M | -13.55M | -15.68M | -14.21M | -12.38M | -10.89M | -8.01M | -5.92M | -4.49M | -5.38M | -5.20M | -3.98M | -5.58M | -5.82M | -5.56M | -6.20M | -4.99M | -4.13M | -3.85M | -2.59M | -2.65M | -3.82M | -3.51M | -2.88M | -5.32M | -2.77M |
| Net Income | - | -11.57M | -12.36M | - | -9.50M | -17.78M | -19.37M | -15.34M | -13.86M | -12.10M | -10.69M | -7.96M | -4.74M | -4.49M | -5.38M | -2.89M | -3.99M | -5.58M | -5.34M | -5.45M | -5.87M | -4.90M | -4.03M | -3.51M | -2.65M | -2.50M | -3.85M | -3.67M | -3.40M | -5.27M | -3.06M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.20 | -1.20 | -1.20 | -1.24 | -1.03 | -0.68 | -0.53 | -0.38 | -0.31 | -0.47 | -0.44 | -0.40 | -0.59 | -0.33 |
| R&D Expense | - | 2.77M | 1.88M | - | 2.31M | 4.37M | 2.33M | - | 3.46M | 2.51M | 2.27M | 1.52M | 1.03M | 629.00K | 499.00K | 825.00K | 470.00K | 934.00K | 1.34M | 1.62M | 1.81M | 1.16M | 1.25M | 399.00K | 635.00K | 521.00K | 642.00K | 511.00K | 662.00K | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 811.46K | 992.95K | 2.39M | 3.50M | 5.45M | 8.59M | 16.03M | 25.18M | 32.03M |
| Gross Profit | 292.93K | 414.21K | 1.23M | 1.76M | 4.07M | 6.98M | 13.23M | 21.40M | 27.79M |
| Operating Income | -25.64M | -54.55M | -46.09M | -24.75M | -20.04M | -22.87M | -19.27M | -12.16M | -13.15M |
| Net Income | -35.79M | -55.82M | -45.15M | -23.51M | -17.22M | -22.16M | -18.83M | -11.89M | -13.97M |
| Diluted EPS | - | - | - | - | -4.36 | -4.69 | -3.42 | -1.59 | -1.65 |
| R&D Expense | 7.83M | 12.47M | 9.90M | 4.20M | 2.54M | 5.52M | 5.32M | 2.36M | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 39.23M | 73.50M | 35.46M | 31.52M | - | 24.76M | 16.10M | 20.47M | 18.67M |
| Current Assets | - | - | - | - | - | - | 21.17M | 14.29M | 16.30M | 15.67M |
| Cash & Equivalents | 416.34K | 13.22M | 7.60M | 13.56M | 4.24M | - | 17.71M | 10.33M | 3.70M | 7.04M |
| Inventory | - | - | - | - | - | - | 1.98M | 2.16M | 1.68M | 1.63M |
| Receivables | - | - | - | - | - | - | 401.00K | 717.00K | 1.37M | 1.03M |
| Total Liabilities | - | 6.43M | 7.32M | 10.56M | 7.87M | - | 7.67M | 8.66M | 12.93M | 20.38M |
| Current Liabilities | - | 6.12M | 7.07M | 9.14M | 5.89M | - | 7.04M | 8.12M | 9.15M | 11.35M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | 6.61M |
| Total Debt | - | - | - | - | - | - | 699.00K | 626.00K | 4.14M | 9.40M |
| Total Equity | - | -90.07M | 65.55M | 24.26M | 23.01M | - | 17.09M | 7.44M | 7.54M | -1.71M |
| Shares Outstanding | - | - | - | - | - | - | 4.74M | 6.00M | 6.65M | 8.00M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -25.33M | -47.11M | -45.07M | -20.05M | - | -16.64M | -14.67M | -6.95M | -8.19M |
| Investing Cash Flow | -24.12M | -36.83M | 50.97M | -7.96M | - | 0 | -206.00K | -8.52M | 3.88M |
| Financing Cash Flow | 62.49M | 78.33M | 160.84K | 18.90M | - | 0 | 7.49M | 8.44M | 7.63M |
| Capital Expenditure | -152.53K | -278.92K | -69.67K | - | - | - | -206.00K | - | -66.00K |
| Free Cash Flow | -25.48M | -47.39M | -45.14M | - | - | -16.64M | -14.87M | -6.95M | -8.25M |
| Net Change in Cash | - | - | - | - | - | -16.64M | -7.39M | -7.03M | 3.32M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 36.1% | 41.7% | 51.6% | 50.3% | 74.6% | 81.2% | 82.5% | 85.0% | 86.8% |
| Operating Margin % | -3,160.3% | -5,494.1% | -1,928.2% | -707.9% | -367.7% | -266.2% | -120.2% | -48.3% | -41.1% |
| Net Margin % | -4,410.9% | -5,621.7% | -1,888.8% | -672.5% | -315.9% | -257.9% | -117.5% | -47.2% | -43.6% |
| ROE % | 39.7% | -85.2% | -186.1% | -102.2% | - | -129.7% | -253.1% | -157.6% | 817.2% |
| ROCE % | -77.4% | -82.1% | -175.1% | -96.6% | - | -129.2% | -241.5% | -107.4% | -179.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Vanguard Capital Management LLC | 2.35% | 211.64K | $2.47M |
| 2 | FourWorld Capital Management, LLC | 1.04% | 94.00K | $1.10M |
| 3 | Wexford Capital LP | 1.02% | 92.06K | $1.08M |
| 4 | Geode Capital Management, LLC | 0.81% | 73.15K | $854.38K |
| 5 | Northern Trust Corporation | 0.74% | 66.51K | $776.79K |
| 6 | Jane Street Group, LLC | 0.70% | 63.40K | $740.53K |
| 7 | Jaffetilchin Investment Partners, LLC | 0.65% | 58.20K | $679.75K |
| 8 | Wealthspire Advisors, LLC | 0.53% | 47.50K | $554.78K |
| 9 | Citadel Advisors Llc | 0.49% | 43.80K | $511.62K |
| 10 | Marshall Wace LLP | 0.48% | 43.67K | $510.09K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ECOR
(ECOR) Volatility Zones as Tactical Triggers - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxPeUd1WVNKb2FuSDNoVlRVVWwwVTJGd1RoTkpaandadmN5TlpsZUNlQ0tMUndNVm9UT1lqY0xjMnJPRUh6U09KU3JEcS00TFcwSUx2TmdVYml1QzVSX19aZ2M0VHRCOHQ4VnQwUWhIZFNNbF9kdlFDRjUyZmVydnI1WGUzbzZzRks4eTA3NF…
electroCore (ECOR) director boosts stake with 5,000-share buy - Stock Titan
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxOY1VYWXl6Z1ZxallVU1FfR0lkTHQwck43NTkzVDdIcGpmZXlzbmU5eE56U0paT0FEWDNHQ0Y5bi1qS3lZYWMwamFGRW1wSG0xV1RrejkyS1AySHpwQ0loNDd0ZzlOTkE5VDNTTDVVWmIxN1VCMVFLVDF6V2tKNEpmR3g3TzlGNFVqM2h1QU…
$ECOR stock is up 24% today. Here's what we see in our data. | ECOR Stock News - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxOSnMxdzdodlk4MUkxRjhDd2U0c1NNc1lCcGdJbmVDUHU3R2Rub0U1SE55NzBqQTZNZ0hSRmdES2NpOFFFcUg1YXFVSmFaekl5UHBoeld3bWctZ2FmamtIQWk5eVFtTE5VelA3NXNGYTNOaUZqX2J4czI0VFphM05sS1VxWFUtUHN0YWJpb0…
ECOR Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE9CY3BGREUxZ2V0Q3MtVW9Eem9BUS0ydGNmZGhrSHd1cXgxcGQxN09DSXYwN29sNXphTDVCZ2N4ZXhscV9YSXhxMEZPYTdnU29TRTJHV2RCR3llWkE1MHphXzJsYUJDNGNzSS05OGxRdlMtZXZtS1lqSWpn?oc=5" target="_blank">ECO…
ECOR - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE9sbEVyVHhfcDl5ZHhTSF9hZlZpNHRiRUVxWkdXNFpGUkRqWkYtZmtXa0ZKVUNtMlBOZ0gtYmpfZ0ppYlJ1SFE?oc=5" target="_blank">ECOR</a> <font color="#6f6f6f">Finviz</font>…
electroCore, Inc. (NASDAQ:ECOR): When Will It Breakeven? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxONjZyZ3hnNEJSOE05Y1AyQmVpWElRbG56Y1dpdWlEMEQ3Y2NheDB0OXUwb1N6Z1QxZWVfdng4QTZTcEJjeXYwdGJWa290UmZLLTVUTENUUEZWWUhmcXJaY2s5eTNCRUdyWmdMZk05cS1lYVg1MjVENnZzdVFuV3cydnQwSG93emplRk1mbF…
ECOR — Frequently Asked Questions
What is the current share price of electroCore, Inc. (ECOR)?
As of 2026-09-19 21:16 PDT, electroCore, Inc. (ECOR) trades at $9.08 on NasdaqCM. Its 52-week range is $4.42 to $10.81.
What is the market capitalisation of ECOR?
electroCore, Inc. (ECOR) has a market capitalisation of $81.86M on NasdaqCM.
What is the P/E ratio of ECOR?
ECOR trades at a trailing price-to-earnings (P/E) ratio of -5.50. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -29.00.
Is ECOR a good stock to buy?
This page provides a data-driven analysis of electroCore, Inc. (ECOR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.